CVC  MedImmune Ventures

http://medimmuneventures.com





     Office Locations:

One MedImmune Way
Gaithersburg, MD 20878
Phone: 301-398-0000
Fax: 301-398-8170

Get all office locations for this firm with a National Database subscription.
 

Stages:

  • Early
  • Expansion
  • Growth


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    As a wholly-owned venture capital fund within the AstraZeneca Group, MedImmune Ventures (MV) invests in private companies which develop small and large molecules, vaccines, pharmaceutical technologies and platforms. The firm also seeks investments in medical devices, diagnostics, imaging and healthcare IT which pertain to the discovery, development and commercialization of pharmaceutical products. MV's therapeutic scope is broad, as is its geographic interest. While MV had initially focused on North America, the firm will currently consider companies anywhere in the world where it has strong local relationships. Stage-wise, MV invests in companies with early to late stage products and technologies, in early (e.g. seed) to late (e.g. mezzanine) rounds of financing. With $400M under management in an evergreen fund, MV has invested in over 30 companies since 2002.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Isai Peimer Principal
    Michael Gutch PhD Managing Director
    Ron Laufer MD Senior Managing Director
    Samuel Wu MD, PhD Managing Director
    Tyrell Rivers PhD Senior Associate

     

    Portfolio companies include:


      Adheron Therapeutics
        web link


      AGTC
        web link


      Ambit Biosciences
        web link


      Applied Genetic Technologies (AGTC)
        web link


      Arginetix
        web link


      BrainCells
        web link


      Catabasis
        web link


      Cerapedics
        web link


      Coferon
        web link


      CorridorPharma
        web link


      Elusys
        web link


      G1 Therapeutics
        web link


      Hydra Biosciences
        web link


      Inotek Pharmaceuticals
        web link


      Ligocyte Pharmaceuticals
        web link


      Micromet
        web link


      NeuProtect
        web link


      NKT Therapeutics
        web link


      Rib-X Pharmaceuticals
        web link


      Synovex
        web link


      Vaxinnate
        web link


      VentiRx Pharmaceuticals
        web link


      VLST
        web link


      Xencor
        web link


     

    Recent News: